Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-17 | Modus Therapeutics Holding | Notice to Annual General Meeting in Modus Therapeutics Holding | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-17 | Modus Therapeutics Holding | Kallelse till årsstämma i Modus Therapeutics Holding | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-11 | Modus Therapeutics Holding | Modus Therapeutics Holding AB (publ) offentliggör årsredovisning för räkenskapsåret 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-11 | Modus Therapeutics Holding | Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-28 | Penser Future by Carnegie | Penser Future by Carnegie: Modus Therapeutics Holding - Skuldfria och breddad portfölj | Pressreleaser | Visa Stäng |
|
||||
2024-02-21 | Modus Therapeutics Holding | Modus Therapeutics publishes year-end report for 2023 | Rapporter | Ladda ner | Visa Stäng |
Rapporter |
Modus Therapeutics publishes year-end report for 2023STOCKHOLM, SWEDEN – 21 February 2024: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes a year-end report for 2023. The report is available as an attached document and on the company’s website (www.modustx.com). Below is a summary of the interim report. John Öhd, Modus Therapeutics’ CEO, commented:” 2023 has been a very important and exciting year for Modus Therapeutics. With positive top-line data for our main candidate sevuparin against serious systemic inflammations such as sepsis and endotoxemia, new research from cell to human that shows sevuparin’s potential in additional therapeutic areas as well as secured financing, we have laid the foundation for a new phase in the company’s development. The fourth quarter in figures
The full year in figures
Important events during the quarter
Important events after the end of the period CEO John Öhd will provide comments on the report in an interview with Jonathan Furelid on February 23 at 11:00 Link to Interview: https://www.youtube.com/live/FeVkg1twfqQ?si=iZxJ09SItLgS98IG |
||||
2024-02-21 | Modus Therapeutics Holding | Modus Therapeutics offentliggör bokslutskommuniké för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-12-13 | Modus Therapeutics Holding | The Rights Issue is Registered and Trading in Paid Subscribed Shares Ceases | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-13 | Modus Therapeutics Holding | Företrädesemissionen är registrerad och handel med BTA upphör | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-11 | Modus Therapeutics Holding | Modus Therapeutics presenterade data om sevuparin som visar dess potential att behandla anemi vid kronisk njursjukdom vid det årliga mötet American Society of Hematology (ASH) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-11 | Modus Therapeutics Holding | Modus Therapeutics presented data on sevuparin demonstrating its potential to treat anemia in chronic kidney disease at the annual American Society of Hematology (ASH) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-05 | Modus Therapeutics Holding | Modus Therapeutics Holding AB Announces Final Outcome in Rights Issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-05 | Modus Therapeutics Holding | Modus Therapeutics Holding AB offentliggör slutligt utfall i företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Modus Therapeutics Holding | Modus Therapeutics presenterar vid Erik Penser Banks Bolagsdag | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Modus Therapeutics Holding | Modus Therapeutics bjuder in till livesänd vd-intervju med fokus på förestående företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Modus Therapeutics Holding | Modus Therapeutics Holding AB offentliggör prospekt med anledning av förestående företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Modus Therapeutics Holding | Modus Therapeutics Holding AB Publishes Prospectus in Connection with the Upcoming Rights Issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-08 | Modus Therapeutics Holding | Modus Therapeutics Holding AB genomför företrädesemission om 40,3 MSEK och kvittningsemission om 20,3 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-08 | Modus Therapeutics Holding | Modus Therapeutics Holding AB Conducts a Rights Issue of 40.3 MSEK and an Offset Issue of 20.3 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-08 | Modus Therapeutics Holding | Modus Therapeutics offentliggör delårsrapport för tredje kvartalet 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-08 | Modus Therapeutics Holding | Modus Therapeutics publishes interim report for the third quarter 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-02 | Modus Therapeutics Holding | Modus Therapeutics presenterar vid American Society of Hematology Meeting and Exposition 2023 (ASH): Nya data med sevuparin och dess potential att behandla anemi vid kronisk njursjukdom och minska njurskada. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-02 | Modus Therapeutics Holding | Modus Therapeutics to present at the 2023 American Society of Hematology Meeting and Exposition (ASH): New data on sevuparin and its potential to treat chronic kidney disease anemia and reduce kidney injury. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-05 | Modus Therapeutics Holding | Modus Therapeutics presenterar slutliga data från sin Fas 1b LPS-provokationsstudie med sevuparin vid den årliga ISICIP-kongressen i Barcelona | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-05 | Modus Therapeutics Holding | Modus Therapeutics presents final data from its Phase 1b LPS-provocation study with sevuparin at the annual ISICIP symposium in Barcelona | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-31 | Penser Future | Penser Future: Intervju med Modus Therapeutics - Erik Penser Bank - 16 augusti 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-08-24 | Penser Future | Penser Future: Breddar IP-portföljen - Modus Therapeutics Holding | Pressreleaser | Visa Stäng |
|
||||
2023-08-23 | Modus Therapeutics Holding | Modus Therapeutics publishes interim report for the second quarter 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-23 | Modus Therapeutics Holding | Modus Therapeutics offentliggör delårsrapport för andra kvartalet 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-06-12 | Penser Future | Penser Future: Hög potential till hög risk - Modus Therapeutics Holding | Pressreleaser | Visa Stäng |
|
||||
2023-06-12 | Modus Therapeutics Holding | Modus Therapeutics presenterade nya data som visar på potentialen för sevuparin som behandling vid anemi relaterad till kroniska sjukdomar på den årliga kongressen European Hematology Association Congress | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-12 | Modus Therapeutics Holding | Modus Therapeutics presented new data on sevuparin demonstrating its potential to treat anemia related to chronic diseases at the annual European Hematology Association Congress | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-12 | Modus Therapeutics Holding | Modus Therapeutics presenterar på den årliga kongressen European Hematology Association. Nya data med sevuparin ger potential att behandla anemi vid kronisk sjukdom genom att hämma hepcidin | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-12 | Modus Therapeutics Holding | Modus Therapeutics to present at the annual European Hematology Association Congress, new data on sevuparin and its potential to treat anemia of chronic disease by suppression of hepcidin | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-11 | Modus Therapeutics Holding | Årsstämma i Modus Therapeutics Holding AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-11 | Modus Therapeutics Holding | Annual General Meeting in Modus Therapeutics Holding AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|